Liquid Biopsy Response Evaluation Criteria in Solid Tumors (LB-RECIST).

Circulating Tumor DNA Evaluation Liquid Biopsy Response Survival

Journal

Annals of oncology : official journal of the European Society for Medical Oncology
ISSN: 1569-8041
Titre abrégé: Ann Oncol
Pays: England
ID NLM: 9007735

Informations de publication

Date de publication:
23 Dec 2023
Historique:
received: 28 06 2023
revised: 17 10 2023
accepted: 09 12 2023
medline: 26 12 2023
pubmed: 26 12 2023
entrez: 25 12 2023
Statut: aheadofprint

Résumé

Current evaluation of treatment response in solid tumors depends on dynamic changes in tumor diameters as measured by imaging. However, these changes can only be detected when there are enough macroscopic changes in tumor volume, which limits the usability of radiological response criteria in evaluating earlier stages of disease response and necessitates much time to lapse for gross changes to be notable. One promising approach is to incorporate dynamic changes in circulating tumor DNA (ctDNA), which occur early in the course of therapy and can predict tumor responses weeks before gross size changes manifest. However, several issues need to be addressed before recommending the implementation of ctDNA response criteria in daily clinical practice such as clinical, biological, and regulatory challenges and, most importantly, the need to standardize/harmonize detection methods and ways to define ctDNA response and/or progression for precision oncology. Herein, we review the use of liquid biopsy to evaluate response in solid tumors and propose a plan towards standardization of Liquid Biopsy Response Evaluation Criteria in Solid Tumors (LB-RECIST).

Identifiants

pubmed: 38145866
pii: S0923-7534(23)05114-1
doi: 10.1016/j.annonc.2023.12.007
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2023 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved.

Auteurs

M A Gouda (MA)

Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center. Houston, TX, United States.

F Janku (F)

Monte Rosa Therapeutics, Boston, MA, United States.

A Wahida (A)

Division of Gynecological Oncology, National Center for Tumor Diseases (NCT), Heidelberg, Germany.

L Buschhorn (L)

Division of Gynecological Oncology, National Center for Tumor Diseases (NCT), Heidelberg, Germany.

A Schneeweiss (A)

Division of Gynecological Oncology, National Center for Tumor Diseases (NCT), Heidelberg, Germany.

N Abdel Karim (N)

Inova Schar Cancer Institute, Fairfax, VA, United States.

D De Miguel Perez (D)

Center for Thoracic Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, United States.

M Del Re (M)

Center for Thoracic Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, United States.

A Russo (A)

Medical Oncology Unit, Papardo Civil Hospital & Department of Human Pathology, University of Messina, Messina, Italy.

G Curigliano (G)

Department of Oncology and Hemato-Oncology, University of Milano, Milano, Italy; Division of Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milano, Italy.

C Rolfo (C)

Center for Thoracic Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, United States.

V Subbiah (V)

Sarah Cannon Research Institute, Nashville, TN, United States. Electronic address: https://twitter.com/VivekSubbiah.

Classifications MeSH